GENPREX INC

GNPX represents Genprex, Inc., a clinical-stage gene therapy company. The company focuses on developing innovative therapies for patients with cancer and diabetes. Its lead product candidates include Oncoprex and GPX-002, which are designed to deliver therapeutic genes to target cells. Genprex is headquartered in Austin, Texas, and its common stock trades on the Nasdaq Capital Market under the ticker symbol GNPX.

Recent performance of GNPX stock can be found on the stock detail page, which displays the latest price, percentage change, and trading volume. As a clinical-stage biotech, GNPX often experiences volatility driven by news related to clinical trials, regulatory updates, and financial reports. For the most current performance data, please refer to the live quotes and charts provided on this page.

Evaluating GNPX's valuation is complex because the company is clinical-stage with no approved products or commercial revenue. Traditional metrics like P/E ratio are not applicable. Instead, investors might consider the company's pipeline progress, potential market size for its therapies, cash position, and R&D expenses. Since GNPX does not generate revenue, valuation often depends on future prospects rather than current earnings.

Yes, GNPX stock can be traded outside regular market hours through pre-market and after-hours sessions, depending on your broker. These sessions typically run from 4:00 a.m. to 9:30 a.m. ET and 4:00 p.m. to 8:00 p.m. ET, respectively. However, trading volume is usually lower, which can lead to wider spreads and increased volatility. Not all brokers offer extended-hours trading, so check with yours.

Genprex does not pay dividends on its common stock. As a clinical-stage biotechnology company, GNPX reinvests any available funds into research and development to advance its gene therapy pipeline. Therefore, investors should not expect dividend income from GNPX. For the latest information on any potential future dividend policy, please refer to the company's official investor relations communications.

Investing in GNPX involves significant risks typical of clinical-stage biotech companies. These include the risk that clinical trials may fail or be delayed, regulatory hurdles, and the need for substantial additional capital to fund operations. The company currently has no approved products, so it relies on financing to sustain its research. Additionally, GNPX's stock price can be highly volatile due to news and market sentiment.